Roche Files BLA For Conjugated Herceptin Follow-On Trastuzumab-DM1
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche has touted the drug's blockbuster potential since strong data from a Phase II study were made public in December, prompting CEO Schwan to announce in April that subsidiary Genentech would file the drug early for accelerated approval.